Di'ao Xinxuekang Capsule Improves the Anti-Atherosclerotic Effect of Atorvastatin by Downregulating the SREBP2/PCSK9 Signalling Pathway

• Autores principales: Jiyi Liang (Autor), Wei Li (Autor), Honglin Liu (Autor), Xiaofen Li (Autor), Chuqiao Yuan (Autor), Wenjun Zou (Autor), Liping Qu (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Statins are the first choice for lowering low-density lipoprotein cholesterol (LDL-C) and preventing atherosclerotic cardiovascular disease (ASCVD). However, statins can also upregulate proprotein convertase subtilisin/kexin type 9 (PCSK9), which in turn might limits the cholesterol-lowering effect...